Literature DB >> 21193355

Should the organs at risk be contoured in vaginal cuff brachytherapy?

Caroline L Holloway1, Eric A Macklin, Robert A Cormack, Akila N Viswanathan.   

Abstract

PURPOSE: To assess the dose to the organs at risk (OARs) and utility of repeated OAR dose-volume histogram calculations in multifraction high-dose-rate vaginal cylinder brachytherapy using 3-dimensional imaging. METHODS AND MATERIALS: Thirty-eight patients (125 fractions) received high-dose-rate brachytherapy to the vaginal vault between January 2005 and October 2005. All patients emptied their bladders before insertion. After each insertion, a CT scan with 2.5-mm slices and contours of the bladder, rectum, and sigmoid was performed. Dose-volume histograms were generated for the D(0.1cc) and D(2cc) for the OAR using a software program created at our institution. Variance component models estimated the within-patient variance of the dose to the OAR between fractions. Predictors of dose to the OAR were identified using linear mixed models.
RESULTS: The within-patient coefficients of variation of total D(0.1cc) dose were bladder 14.0%, rectum 7.9%, and sigmoid 27.6%; for D(2cc), these were 8.1%, 5.9%, and 20.3%, respectively. Intraclass correlations ranged from 0.27 to 0.79. Larger OAR predicted greater total D(0.1cc) and D(2cc). Other predictors of total D(0.1cc) and D(2cc) dose included the size of the cylinder and the length of the treatment field for rectum.
CONCLUSIONS: CT simulation provides a noninvasive assessment of the dose to the bladder, rectum, and sigmoid. The small within-patient variation in doses to the bladder and rectum do not support reporting doses to the OARs beyond the initial fraction.
Copyright © 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21193355     DOI: 10.1016/j.brachy.2010.10.005

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  14 in total

1.  Reduction of rectal doses by removal of gas in the rectum during vaginal cuff brachytherapy.

Authors:  S Sabater; Ma M Sevillano; I Andres; R Berenguer; S Machin-Hamalainen; K Müller; M Arenas
Journal:  Strahlenther Onkol       Date:  2013-09-04       Impact factor: 3.621

2.  Body mass index, dose to organs at risk during vaginal brachytherapy, and the role of three-dimensional CT-based treatment planning.

Authors:  John M Boyle; Oana Craciunescu; Beverley Steffey; Jing Cai; Junzo Chino
Journal:  Brachytherapy       Date:  2014-01-16       Impact factor: 2.362

Review 3.  American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.

Authors:  Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small
Journal:  Brachytherapy       Date:  2016-05-31       Impact factor: 2.362

4.  Effect of rectal enemas on rectal dosimetric parameters during high-dose-rate vaginal cuff brachytherapy: A prospective trial.

Authors:  Sebastià Sabater; Ignacio Andrés; Marina Gascon; Angeles Rovirosa; Marimar Sevillano; Roberto Berenguer; Cristina Camacho-Lopez; Manuel Aguayo; Maria Victoria Villas; Meritxell Arenas
Journal:  Strahlenther Onkol       Date:  2016-01-23       Impact factor: 3.621

5.  Effects of bladder distension on dose distribution of vaginal vault brachytherapy in patients with endometrial cancer.

Authors:  Ozan C Guler; Cem Onal; Ibrahim Acibuci
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

6.  Single versus multichannel applicator in high-dose-rate vaginal brachytherapy optimized by inverse treatment planning.

Authors:  Yasir A Bahadur; Camelia Constantinescu; Ashraf H Hassouna; Maha M Eltaher; Noor M Ghassal; Nesreen A Awad
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

7.  Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer.

Authors:  Lucas Gomes Sapienza; Antonio Aiza; Maria José Leite Gomes; Michael Jenwei Chen; Antonio Cassio de Assis Pellizzon; David B Mansur; Glauco Baiocchi
Journal:  J Contemp Brachytherapy       Date:  2015-10-13

8.  Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma.

Authors:  Eric D Donnelly; Sunpreet Rakhra; Irene Helenowski; Mahesh Gopalkrishnan; John Lurain; Julian Schink; Diljeet Singh; Jonathan Strauss; William Small
Journal:  J Contemp Brachytherapy       Date:  2012-09-29

9.  Volumetric (3D) bladder dose parameters are more reproducible than point (2D) dose parameters in vaginal vault high-dose-rate brachytherapy.

Authors:  Lucas Gomes Sapienza; Adriana Flosi; Antonio Aiza; Antonio Cassio de Assis Pellizzon; Rubens Chojniak; Glauco Baiocchi
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

10.  Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer.

Authors:  Jack M Qian; John M Stahl; Melissa R Young; Elena Ratner; Shari Damast
Journal:  J Gynecol Oncol       Date:  2017-11       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.